PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer
NCT07931313, Phase 2, Phase 3, Not yet recruiting, Shanghai Gynecologic Oncology Group
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer | ClinicalTrials.gov |
| NCT number | NCT07931313 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 2, Phase 3 | ClinicalTrials.gov |
| Enrollment | 534 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Shanghai Gynecologic Oncology Group | ClinicalTrials.gov |
| Conditions | Epithelial Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer | ClinicalTrials.gov |
| Interventions | Upfront cytoreductive surgery, Interval debulking surgery, Platinum-based chemotherapy | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Overall survival | 60 months since randomization | Time from randomization to death from any cause; participants alive will be censored at the last date known alive. | ClinicalTrials.gov |
| Secondary | Progression-free survival | 60 months since randomization | Time from randomization to first disease progression or death from any cause, whichever occurs first. | ClinicalTrials.gov |
| Secondary | Postoperative complications within 30 days after surgery | Through 30 days after the planned debulking procedure | The surgical complications will be evaluated at 30-day after upfront cytoreductive surgery or interval debulking surgery, graded using CTCAE version 5.03 | ClinicalTrials.gov |
| Secondary | Quality of life assessments | At baseline, 6 months, 12 months, and 5 years after randomization. | Quality of life measured with EORTC QLQ-C30 | ClinicalTrials.gov |
| Secondary | Pattern of first relapse | 60 months since randomization | The number and sites of the first relapse, including pelvic, abdominal, retroperitoneal lymph nodes, distant metastases and ascites will be compared between the two groups. | ClinicalTrials.gov |
| Secondary | The rate of 3-year progression-free survival | 36 months since randomization | The rate of the patients without progression or recurrence or death at 3 years. | ClinicalTrials.gov |
| Secondary | The rate of 5-year progression-free survival | 60 months since randomization | The rate of the patients without progression or recurrence or death at 5 years. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)